Search results
Moderna Wins FDA Approval For Second-Ever Product; Why Its RSV Vaccine Could Dominate Pfizer, GSK
Investor's Business Daily· 3 weeks agoModerna stock sank Friday after the Food and Drug Administration approved its RSV vaccine, dubbed...
Moderna's (MRNA) COVID Jab Gets Nod For Kids in Canada
Zacks via Yahoo Finance· 2 years agoModerna MRNA received approval from Canadian regulatory authority, Health Canada, for its mRNA...
Pfizer (PFE), BioNTech Post Data on COVID Jab for Kids Under 5
Zacks via Yahoo Finance· 2 years agoPfizer PFE and partner BioNTech BNTX announced newly-updated data from a phase II/III study,...
Moderna’s sales from its only product, the COVID-19 vaccine, fell 91% from last year
Fortune via Yahoo Finance· 2 months agoThe dark days of the pandemic are finally in the past for most of us—and that seems to be reflected...
A new COVID booster has FDA approval. Here’s when doses could get to Kansas City
Kansas City Star McClatchy Articles via AOL· 2 years agoThe U.S. Food and Drug Administration (FDA) expanded its emergency use authorization on Wednesday to...
Moderna (MRNA) to Report Q4 Earnings: What's in the Cards?
Zacks via Yahoo Finance· 1 year agoInvestors focus will likely be on Moderna's (MRNA) pipeline, especially with its late-stage pipeline...
Moderna starts application process for RSV vaccine for older adults
Reuters via Yahoo News· 12 months agoIt is aiming to be the third vaccine maker to get an approval in the country after GSK and Pfizer...
FDA greenlights updated mRNA Covid vaccines
Politico via Yahoo News· 9 months agoThe FDA on Monday cleared two updated mRNA Covid-19 shots from Pfizer-BioNTech and Moderna, paving the way for an early fall rollout. It will be the...
The Zacks Analyst Blog Highlights Moderna, RAPT Therapeutics, Iovance, Sarepta Therapeutics and...
Zacks via Yahoo Finance· 4 months agoFor Immediate Release Chicago, IL – February 23, 2024 – Zacks.com announces the list of stocks...
Is This a Setback for Moderna?
Motley Fool via Yahoo Finance· 1 month agoInvestors have put their hopes in Moderna's (NASDAQ: MRNA) next potential product, a respiratory syncytial virus (RSV) vaccine. That's because it...
